The infertility testing market size was valued at US$ 494.7 billion in 2024 and is expected to reach US$ 871.3 billion by 2031; it is estimated to record a CAGR of 8.6% from 2025 to 2031.

The infertility testing market is segmented into five major regions-North America, Europe, Asia Pacific (APAC), the Middle East & Africa (MEA), and South & Central America. North America dominated the market in 2024, followed by Europe and the Asia Pacific, respectively.

The female infertility testing segment encompasses a variety of diagnostic procedures aimed at identifying underlying causes of infertility in women. Key tests include hormonal profiling, ovarian reserve assessment, hysterosalpingography (HSG), pelvic ultrasounds, and laparoscopy. Hormonal profiling evaluates levels of hormones such as FSH, LH, AMH, and prolactin, which play critical roles in ovulation and reproductive health. Ovarian reserve testing helps determine the quantity and quality of a woman's eggs, aiding in predicting fertility potential. HSG and hysterosonography are employed to examine the uterine cavity and fallopian tube patency, detecting structural abnormalities or blockages. Advanced imaging and minimally invasive procedures like laparoscopy are used for diagnosing conditions such as endometriosis or pelvic adhesions, which may impair fertility. Rising awareness regarding reproductive health, increasing maternal age, and the prevalence of gynecological disorders are driving demand for female infertility testing. Furthermore, innovations in diagnostic technologies, including genetic testing and non-invasive imaging, are enhancing the accuracy and efficiency of assessments, positioning this segment as a critical component of the overall infertility testing market.

The male infertility testing segment focuses on evaluating factors that affect male reproductive health, contributing to nearly 40-50% of infertility cases globally. Core diagnostic procedures include semen analysis, hormonal testing, genetic testing, and imaging studies. Semen analysis is the most common method, assessing sperm count, motility, morphology, and overall seminal quality. Hormonal testing measures levels of testosterone, FSH, LH, and prolactin, providing insight into endocrine causes of infertility. Genetic testing identifies chromosomal abnormalities or Y-chromosome microdeletions that may impact sperm production or function. Imaging techniques such as scrotal ultrasound or Doppler studies detect structural issues like varicocele or testicular abnormalities.

Infertility testing market future trend: Digital health innovations - ranging from mobile apps and connected at-home diagnostic tools to full telemedicine platforms - are breaking down traditional barriers to care and enabling earlier, more personalized engagement with fertility testing than ever before. Integration of telehealth into fertility diagnostics offers convenience, reduced travel burden, and continuous support that better fits modern lifestyles. For individuals and couples navigating sensitive reproductive health concerns, the ability to connect virtually with specialists and receive timely interpretations of fertility test results has proven essential for engagement and care continuity.

The proliferation of direct-to-consumer fertility testing models blends digital interfaces with clinical diagnostics. Companies such as Modern Fertility and Natalist have pioneered services where customers order hormone test kits online, collect samples at home, receive results electronically, and follow up with expert telehealth consultations - all within a digital ecosystem. Such models improve accessibility and foster ongoing user engagement through personalized digital portals. Digital tools such as fertility tracking apps and wearable monitors are now frequently integrated into diagnostic pathways. These platforms collect real-time physiological data, offer cycle predictions, and enable remote monitoring by healthcare providers - helping to capture critical fertility indicators without repeated in-person clinic visits. Patients report high adoption rates and helpfulness of these tools, reflecting their role in empowering users to understand better and manage reproductive health. In clinical settings, telemedicine is transforming patient-provider interaction by facilitating virtual consultations, remote follow-ups, and digital transmission of test results, which enhance continuity of care and patient satisfaction. This digital transformation is impactful for those in remote areas or with mobility constraints, improving the efficiency and patient experience of fertility diagnostics.

Quest Diagnostics Inc; Church & Dwight Co Inc; Swiss Precision Diagnostics GmbH; bioM?rieux SA; QuidelOrtho Corp; Abbott Laboratories; Thermo Fisher Scientific Inc; Prestige Consumer Healthcare Inc.; LetsGetChecked; and Mira companies are among the key players profiled during this market study. Several other essential market players were also studied and analyzed to get a holistic view of the global infertility testing market and its ecosystem.

The overall infertility testing market size has been derived using both primary and secondary sources. Exhaustive secondary research has been conducted using internal and external sources to obtain qualitative and quantitative information related to the infertility testing market size. The process also helps obtain an overview and forecast of the market with respect to all the market segments. Also, multiple primary interviews have been conducted with industry participants to validate the data and gain analytical insights. This process includes industry experts such as VPs, business development managers, market intelligence managers, and national sales managers, along with external consultants such as valuation experts, research analysts, and key opinion leaders specializing in the infertility testing market.